EGFR-directed monoclonal antibodies such as cetuximab and panitumumab, which inhibit EGFR activation by binding to the extracellular domain of receptor, are currently recommended therapy options in late-stage CRC without RAS and B-Raf (BRAF) mutations [25,26,27]. This evidence concerns the gene BRAF and colorectal carcinoma.